DAS28 responses at 6 months of abatacept treatment in patients stratified by number of previous anti-TNF agents, previous anti-TNF agent and reason for failure of previous anti-TNF agent
Patient subgroup | DAS28 response at 6 months (95% CI) | ||
DAS28 mean change from baseline | LDAS % responders | DAS28-defined remission % responders | |
Type of previous anti-TNF* | |||
Etanercept (n = 278) | −2.0 (−2.2 to −1.8) | 24.1 (19.1 to 29.1) | 14.7 (10.6 to 18.9) |
Infliximab (n = 348) | −2.1 (−2.3 to −2.0) | 21.3 (17.0 to 25.6) | 14.1 (10.4 to 17.7) |
Adalimumab (n = 351) | −1.9 (−2.1 to −1.8) | 23.4 (18.9 to 27.8) | 11.1 (7.8 to 14.4) |
No of previous anti-TNF† | |||
1 (n = 488) | −2.1 (−2.2 to −2.0) | 24.8 (21.0 to 28.6) | 15.8 (12.5 to 19.0) |
2 (n = 340) | −2.1 (−2.3 to −1.9) | 22.9 (18.5 to 27.4) | 12.9 (9.4 to 16.5) |
⩾2 (n = 540) | −2.0 (−2.1 to −1.8) | 20.0 (16.6 to 23.4) | 10.6 (8.0 to 13.1) |
3 (n = 200) | −1.7 (−1.9 to −1.5) | 15.0 (10.1 to 19.9) | 6.5 (3.1 to 9.9) |
Reason for failure‡ | |||
Safety (n = 106) | −2.3 (−2.6 to −2.0) | 30.2 (21.4 to 38.9) | 16.0 (9.1 to 23.0) |
Intolerability (n = 230) | −2.2 (−2.4 to −2.0) | 22.6 (17.2 to 28.0) | 13.5 (9.1 to 17.9) |
Safety or intolerability (n = 305) | −2.2 (−2.4 to −2.0) | 25.6 (20.7 to 30.5) | 14.4 (10.5 to 18.4) |
Efficacy (n = 952) | −2.0 (−2.1 to −1.9) | 20.9 (18.3 to 23.5) | 12.2 (10.1 to 14.3) |
n Numbers are based on patients with available data (as-observed population). *Data were unavailable for 69 patients and are presented for the last anti-tumour necrosis factor (TNF) therapy received before initiating abatacept. †Data were unavailable for 18 patients. ‡Patients could have failed for more than one reason. DAS28, disease activity score in 28 joints; LDAS, low disease activity state.